Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2003
12/10/2003CN1460522A Egg yolk antibody composite for preventing and curing diseases and its preparaion method
12/10/2003CN1460521A Recombinant hepatitis B BCG vaccine combined vaccine and its preparation method
12/10/2003CN1130459C Biological active molecules having potentiating effect on growth hormone biological activity
12/10/2003CN1130227C Viral agent associated with mystery swine disease
12/10/2003CN1130226C Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
12/10/2003CN1130225C Method for purifying necrotoxin produced by bordetella and toxoid
12/10/2003CA2389911A1 Broad spectruma antagonists and vaccines directed against pyrogenic exotoxins
12/09/2003US6660840 Ability to stimulate a Th1 response in peripheral blood mononuclear cells; contain a biologically active portion of a Leishmania braziliensis
12/09/2003US6660723 Activating primate gamma delta lymphocytes
12/09/2003US6660714 α-O-linked glycoconjugates, methods of preparation and uses thereof
12/09/2003US6660513 Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142
12/09/2003US6660512 Human lysozyme gene, it's encoded polypeptide and the method of preparing them
12/09/2003US6660499 Nucleic acid encoding human DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma)
12/09/2003US6660498 Malaria immunogenic composition
12/09/2003US6660495 Tolerogenic fragments of natural allergens
12/09/2003US6660487 Exposing mammal to major histocompatibility complex class I and peptide, prior to, after, or concurrently with treating mammal to kill or inactivate autoimmune cells of mammal for increasing or maintaining number of functional cells
12/09/2003US6660467 Variant of ciliary neurotrophic factor and DNA encoding the variant
12/09/2003US6660276 Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
12/09/2003US6660275 Amplification nucleic acids
12/09/2003US6660274 Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
12/09/2003US6660273 Viable chimeric recombinant flavivirus
12/09/2003US6660272 For protection against Porcine Multisystemic Wasting Syndrome also called Post- weaning Multisystemic Wasting Syndrome
12/09/2003US6660271 Ubiquitin fusion-based vaccine system
12/09/2003US6660270 Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection
12/09/2003US6660269 Canine tropical pancytopenia;
12/09/2003US6660261 Bordetella strain expressing the FHA hybrid, liposomes and vaccines
12/09/2003US6659675 Document folder
12/09/2003CA2229955C Papilloma virus capsomere vaccine formulations and methods of use
12/09/2003CA2171462C Compounds for the prevention and treatment of helminth infections
12/09/2003CA2111580C Immunogen composites with noted anticytokin effect, process of preparation, pharmaceutical compositions and kits containing them
12/09/2003CA2108259C Process of screening plasma samples for effective antibody titers against respiratory viruses
12/09/2003CA2106492C Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a
12/04/2003WO2003100435A2 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
12/04/2003WO2003100432A2 Method for identifying immunoreactive peptides
12/04/2003WO2003100060A2 Muc-1 antigen with reduced number of vntr repeat units
12/04/2003WO2003100040A1 A method for generating antigen-presenting cells
12/04/2003WO2003100033A2 ANTI-αvβ6 ANTIBODIES
12/04/2003WO2003100027A2 Mutant fibronectin and tumor metastasis
12/04/2003WO2003100008A2 Neutralizing human anti-igfr antibody
12/04/2003WO2003100005A2 Universal chimera bank
12/04/2003WO2003099989A2 Compositions and methods relating to breast specific genes and proteins
12/04/2003WO2003099868A2 Method for obtaining anti-idiotype antibodies
12/04/2003WO2003099864A1 Use of monocarboxylate transporter protein for thyroid hormone transport
12/04/2003WO2003099860A2 Immunogenic composition and peptide sequences for prevention and treatment of an hsv condition
12/04/2003WO2003099340A1 Novel chimeric cd154
12/04/2003WO2003099330A1 Induction and maintenance of tolerance to composite tissue allografts
12/04/2003WO2003099329A1 Chimeric allograft tolerance induction, monitoring and maintenance
12/04/2003WO2003099327A1 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
12/04/2003WO2003099326A1 Novel uses of parapoxvirus preparations
12/04/2003WO2003099325A1 Methods for the in vitro culture of sporozoea sp. and user thereof
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099211A2 Mitotic kinesin inhibitors
12/04/2003WO2003099196A2 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099193A2 Vaccines
12/04/2003WO2003099104A2 Elisa assay of serum soluble cd22 to assess tumor burden/relapse in subjects with leukemia and lymphoma
12/04/2003WO2003087322A3 Production of haematophagous organisms and parasites suitable for vaccine production
12/04/2003WO2003083041A3 Cripto-specific antibodies
12/04/2003WO2003072771A3 Method of preparing a treatment product using a togaviridae expression construct
12/04/2003WO2003072736A3 Reagents and treatment methods for autoimmune diseases
12/04/2003WO2003072062A3 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/04/2003WO2003070981A3 Seequences specifically deleted mycobacterium tuberculosis genome and their use in diagnostics and as vaccines
12/04/2003WO2003068201A3 High affinity antibody having a tcr-like specificity and use in detection and treatment
12/04/2003WO2003065787A3 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
12/04/2003WO2003063899A3 Vaccine adjuvant based on a cd4 0 ligand
12/04/2003WO2003063785A3 Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
12/04/2003WO2003061578A3 Compositions for treatment or prevention of bioterrorism
12/04/2003WO2003060468A3 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease
12/04/2003WO2003059379A3 Immunogenic carcinoembryonic antigen (cea)
12/04/2003WO2003057852A3 Purification and characterization of hla proteins
12/04/2003WO2003057168A3 Cancer-associated epitope
12/04/2003WO2003055439A3 Her2/neu target antigen and use of same to stimulate an immune response
12/04/2003WO2003053465A3 Lyophilized preparation containing antibodies to the egf receptor
12/04/2003WO2003050122A3 Mitotic kinesin inhibitors
12/04/2003WO2003048328A3 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
12/04/2003WO2003035010A3 Thymosin augmentation of genetic immunization
12/04/2003WO2003031462A3 Nogo receptor-mediated blockade of axonal growth
12/04/2003WO2003025003A3 Hiv-gag codon-optimised dna vaccines
12/04/2003WO2003025002A3 Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
12/04/2003WO2003022879A3 Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them
12/04/2003WO2003021273A3 Diagnosis of carcinomas
12/04/2003WO2003020900A3 Compositions and methods relating to breast specific genes and proteins
12/04/2003WO2003017941A3 Flexible applicator for applying oil-in-water emulsion with improved stability
12/04/2003WO2003016491A3 Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
12/04/2003WO2003009704A3 Enteral compositions for the prevention and/or treatment of sepsis
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2003007987A3 Haptenizing cancer cell components for the preparation of cancer vaccines
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002099068A3 LCES AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/04/2003WO2002086090A3 Identification of essential genes of aspegillus fumigatus and methods of use
12/04/2003WO2002082077A3 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
12/04/2003WO2002080965A3 Vaccine composition
12/04/2003WO2002074193A3 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
12/04/2003WO2002070708A3 Glutamate receptor modulatory proteins and nucleic acids encoding them
12/04/2003WO2002069985A8 Immune response potentiation
12/04/2003WO2002069840A3 Nucleic acids for transforming fish cells and methods for their use
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003WO2002039431A3 Compositions and methods relating to prostate specific genes and proteins
12/04/2003WO2002036806A9 Expression vectors able to elicit improved immune response and methods of using same
12/04/2003WO2002030462A3 Hedgehog antagonists, methods and uses related thereto
1 ... 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 ... 1823